Arkolith/Insider Trading/TSHA/Form 4

Nagendran Sukumar

President and Head of R&D, DirectorTaysha Gene Therapies, Inc. (TSHA) · full profile →Form 4 · filed Jan 14, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$942K
Net Open-Market Flow
-$942K
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Option exercise(M)89K$1.71$152K1.2M
Jan 12, 2026Option exercise(M)111K$0.70$78K1.1M
Jan 12, 2026Sell(S)200K$4.71$942K1.0M
Jan 12, 2026Grant(A)427K—$01.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Option exercise(M)111K—$0111K
Jan 12, 2026Option exercise(M)89K—$0475K
Jan 12, 2026Grant(A)274K—$0274K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001665124-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML